Skip to main content

*Mankind Pharma and Daewoong Pharmaceutical Announce Initiation of Phase 1 Clinical Trial on a ‘Novel’ Formulation of Niclosamide (DWRX2003) for COVID-19 Treatment*

New Delhi, 11th August 2020: Daewoong Pharmaceutical Co., Ltd., South Korea (through its subsidiary, Daewoong Pharmaceutical India Pvt. Ltd.) and Mankind Pharma, fastest growing Indian Pharmaceutical Company, have collaborated for conducting Phase I clinical trial of a long acting intramuscular formulation of Niclosamide. The trial is designed towards addressing the need for a science-based investigation on this new formulation “Niclosamide (DWRX2003)” based on encouraging preclinical evidence for the treatment of COVID-19.


Niclosamide (DWRX2003) is already in clinical use as an anthelmintic; however, the current formulation is expected to be a longer acting variant for this alternate clinical indication. It is also expected to circumvent the downside of oral administration.


In vitro, Niclosamide (DWRX2003) was found to be 40, 26 & 15 times more potent than Remdesivir, Chloroquine & Ciclesonide respectively for its anti-viral action against SARS-CoV-2 virus. Also, the injectable intramuscular (IM) formulation of Niclosamide successfully removed the virus from lungs in animal tests, thereby countering viral infection, besides preventing cytokine storm which is the major cause of mortality in moderate to severe cases of COVID-19. 


Through intensive motivated research, Daewoong researchers worked on quick development of the formulation to have reached the stage of “First-in-Human” evaluation, successful completion of which would immensely facilitate COVID-19 disease treatment. 


Mr. Arjun Juneja, COO, Mankind Pharma Ltd. commented “We are continuously evaluating various target products for the treatment of Covid-19 in support to national response to COVID-19 pandemic. 


In continuation to Mankind Pharma vision to service society by bringing quality and affordable medicine. We are excited to collaborate with Daewoong Pharmaceutical Co., Ltd. to bring Novel formulation of Niclosamide (DWRX2003) for the treatment of COVID-19 patients in India. We believe that the product would provide for a safe and effective alternative to patients suffering from this disease”.


We are already working on other unrelated COVID-19 focussed programs, in tandem with community and society as part of our Corporate Social Responsibility initiatives.


Sengho Jeon, CEO of Daewoong Pharmaceutical commented “Through development of candidates for COVID-19 treatments such as Nicosamide, which Daewoong Pharmaceutical is currently developing, we expect to provide innovative treatment option for patients suffering from COVID-19. 


I believe Mankind Pharma is one of the best partner to accelerate the clinical development and supply of DWRX2003 for India"


About Daewoong Pharmaceutical: Established in 1945, Daewoong Pharmaceutical Co., Ltd. is a South Korea based global healthcare group that develops, manufactures, and commercializes pharmaceuticals for both the domestic and international markets. Daewoong has constructed various collaboration infrastructure including research, development, manufacturing, sales, etc. with clients & actively distributes products desired by local markets to strengthen its local competitiveness. Daewoong has eight branch offices in India, Asia and USA, five R&D centers and more than 100 partners worldwide. 


About Mankind Pharma: Mankind is one of the top 5 leading pharmaceutical companies in India with a top line revenue approximating 1 billion USD. Mankind Pharma is a fully-integrated pharmaceutical company established in 1995 with a wide range of prescription and OTC products & a significant employee base of more than 14000. The global footprint of Mankind spreads across USA, Asia, Africa, Latin America & CIS Nations with presence in more than 30 countries. Mankind Research Centre (MRC), based at Manesar near Gurugram in Delhi/NCR, is a state of the art research facility with over 550 scientists involved in complex and innovative research. Since inception, Mankind Pharma’s mission statement has been to provide cost-effective, affordable & innovative superior quality pharmaceutical products across the globe to improve the lives of the patients.


Popular posts from this blog

छतरपुर जिला चिकित्सालय को मिलेअत्याधुनिक जांच उपकरण एस्सेल माइनिंग द्वारा सी-आर्म, रक्त जांच एवं अन्य उपकरण दान

 छतरपुर की स्वास्थ्य अधोसंरचना को मजबूत बनाने के ध्येय को आगे बढ़ाते हुए एस्सेल माइनिंग द्वारा शुक्रवार को छतरपुर जिला चिकित्सालय में अत्याधुनिक सी-आर्म इमेजिंग डिवाइस, हाई फ़्लो नैज़ल कैनुला समेत त्वरित रक्त जांच उपकरण एवं मोरचुरी फ्रीजर भेंट किया गया।  जिला कलेक्टर श्री संदीप जी आर ने फीता काटकर नई सुविधाओं का शुभारंभ किया। इस अवसर पर मुख्य चिकित्सा एवं स्वास्थ्य अधिकारी डॉ विजय पथोरिया एवं अस्पताल के अन्य अधिकारी-कर्मचारी उपस्थित रहे। नए उपकरणों के साथ छतरपुर जिला चिकित्सालय के सुविधाओं में वृद्धि होने के साथ ही हजारों नागरिकों को नई जाँचों का लाभ मिल सकेगा और त्वरित जांच प्राप्त हो सकेगी।कलेक्टर श्री श्री संदीप जी आर द्वारा इस अवसर पर अस्पताल परिसर में पौधा रोपण भी किया गया।  एस्सेल माइनिंग द्वारा लगातार छतरपुर जिले की स्वास्थ्य सेवाओं को उन्नत बनाने में सतत योगदान दिया जा रहा है। पूर्व में गुरुवार को कंपनी द्वारा बक्सवाहा के सामुदायिक स्वास्थ्य केंद्र को बड़ा मलहरा विधायक श्री प्रद्युम्न सिंह लोधी की उपस्थिति में एडवांस्ड लाइफ सपोर्ट एम्बुलेंस भेंट की गई। वेंटीलेटर जैसी सुविधाओं के सा

*Reusable pads essential to make menstrual hygiene sustainable for all women and girls*

 If every woman and girl of menstruating age in India used disposable pads, 38,500,000,000 used pads would be discarded every month – an environmental disaster since each of these would take 500-800 years to degrade naturally XXX / May 26, 2021: Considering the immense non-biodegradable waste generated by disposable sanitary pads every month, sustainable menstrual hygiene in India can be achieved only with reusable pads made of organic material, said Anju Bist, Co-Director, Amrita SeRVe (Self Reliant Village) Program of Mata Amritanandamayi Math. Known as the “Pad Woman” of India for her zeal in promoting the use and reuse of sanitary pads made of cloth and banana fibre, she is the co-creator of Saukhyam Reusable Pads which have been awarded as the "Most Innovative Product" by the National Institute of Rural Development, Hyderabad. The pads were also lauded at the UN Climate Change Conference held in Poland in 2018. Said Anju Bist: “There are 355 million menstruating women an

*GLENEAGLES GLOBAL HEALTH CITY PERFORMS WORLD’S SECOND SUCCESSFUL PEDIATRIC COMBINED LIVING DONOR LIVER AND KIDNEY TRANSPLANT FOR A RARE GENETIC LIVER DISORDER*

 12-year-old boy with rare liver disease undergoes successful multi-organ transplant making him the 2nd case in the world and 1st in the country Chennai, 7th December, 2021: Gleneagles Global Health City (GGHC), a leading multi-organ transplant centre in Asia, successfully performed India’s first live donor liver and kidney transplant on a 12-year-old who was suffering from a rare genetic disorder – Primary Hyperoxaluria type 2. Master Anish*, a 12-year-old, was referred from Bangalore with renal failure and had been on dialysis three times a week. Doctors in Bangalore had diagnosed him with a rare genetic disorder called Primary Hyperoxaluria (PH) type- II, which is a liver condition that results in accumulation of oxalate in the kidneys, heart and bones and other organ systems of the body. As the disease is primarily based in the liver, these patients need combined liver and kidney transplantation for cure which is a major undertaking, especially in a child.  Across the world, there